@frostmourne 1 month ago
Moderna is up 600% this year and just joined the Nasdaq-100
Moderna is up 600% this year and just joined the Nasdaq-100
Moderna (MRNA) has rallied over 600% this year, outperforming a lot of the major AI stocks. They were also just added to the Nasdaq-100 index.
After a rough patch due to falling Covid vaccine demand and a failed phase 3 trial for a CMV vaccine, the company cut costs and shifted focus to oncology. The big catalyst came in August when their personalized cancer vaccine, paired with Merck's Keytruda, met phase 3 goals for melanoma. They are now preparing to file for regulatory approval.
The stock is currently trading around $225. That is significantly higher than the average Wall Street price target of $122. It looks like a solid turnaround, but given the massive run up, it might be better to wait for a pullback before starting a position.

www.fool.com
| Meet the New Nasdaq-100 Stock That's Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? | The Motley Fool

There are no comments here, be the first to comment